NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the second quarter ended June 30, 2016.
Recent Highlights
• DaxibotulinumtoxinA for Injection (RT002) ? Completed enrollment of the second cohort of patients in a Phase 2 dose-escalating study of RT002 injectable to treat cervical dystonia, a neurological muscle movement disorder.
Recent Highlights
• DaxibotulinumtoxinA for Injection (RT002) ? Completed enrollment of the second cohort of patients in a Phase 2 dose-escalating study of RT002 injectable to treat cervical dystonia, a neurological muscle movement disorder.
